Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
| Company Name | Founded | Funding Stage | Amount | City |
|---|---|---|---|---|
| Immunic Therapeutics | 2026 | Post Ipo Equity | $400.0M | New York |
| Coherus Biosciences | 2026 | Post Ipo Equity | $50.1M | Redwood City |
| Gyala Therapeutics | 2026 | Grant | Undisclosed | Barcelona |
| Kinaset Therapeutics | 2026 | Series B | $103.0M | Boston |
| Clene Nanomedicine | 2026 | Post Ipo Equity | $28.0M | Salt Lake City |
| EpiBiologics | 2026 | Series B | $107.0M | San Mateo |
| CAMP4 Therapeutics | 2025 | Post Ipo Equity | $30.0M | Cambridge |
| BlossomHill Therapeutics | 2025 | Series B | $84.0M | San Diego |
| Sanegene Bio | 2025 | Series B | $110.0M | Woburn |
| Biohaven Pharmaceutical | 2025 | Post Ipo Equity | $200.0M | New Haven |
| # | Company | Stage | Amount | Location |
|---|---|---|---|---|
| 26 | Immunic Therapeutics | Post Ipo Equity | $400.0M | New York, United States |
| 27 | Coherus Biosciences | Post Ipo Equity | $50.1M | Redwood City, United States |
| 28 | Gyala Therapeutics | Grant | Undisclosed | Barcelona, Spain |
| 29 | Kinaset Therapeutics | Series B | $103.0M | Boston, United States |
| 30 | Clene Nanomedicine | Post Ipo Equity | $28.0M | Salt Lake City, United States |
| 31 | EpiBiologics | Series B | $107.0M | San Mateo, United States |
| 32 | CAMP4 Therapeutics | Post Ipo Equity | $30.0M | Cambridge, United States |
| 33 | BlossomHill Therapeutics | Series B | $84.0M | San Diego, United States |
| 34 | Sanegene Bio | Series B | $110.0M | Woburn, United States |
| 35 | Biohaven Pharmaceutical | Post Ipo Equity | $200.0M | New Haven, United States |
Immunic is a biopharmaceutical company that develops a pipeline of selective oral immunology therapies.
Coherus Biosciences develops, manufactures, and commercializes biologic therapeutics for oncology and inflammatory diseases.
Gyala Therapeutics is focused on developing new CAR-T therapies for treating hematological malignancies.
Kinaset Therapeutics is a biopharma company that focuses on advancement of novel drugs in areas of unmet medical needs.
Clene Nanomedicine focuses on the development of unique therapeutics for neurodegenerative diseases.
EpiBiologics develops antibody-based targeted therapies against membrane and extracellular proteins.
CAMP4 Therapeutics is a biotechnology company that uses RNA to restore healthy gene expression.
BlossomHill Therapeutics is a biopharmaceutical company focusing on oncology and autoimmune disorders.
Sanegene Bio develops an RNAi drug discovery platform designed for unmet clinical needs.
Biohaven is a biopharmaceutical company that develops drug candidates targeting neurological diseases.
Zenas BioPharma is a biopharmaceutical company that focuses on developing immune-based therapies for patients.
Cidara Therapeutics develops targeted immunotherapies aimed at improving treatment outcomes for patients with serious diseases.
IO Biotech is a clinical-stage biotech company developing disruptive immune therapies for the treatment of cancer.
Semnur Pharmaceuticals is a specialty pharmaceutical company focusing on clinical and commercial development of innovative products.
Integra Therapeutics is a developer of next generation of gene editing tools to cure diseases.
Celcuity is a biotechnology company translating discoveries of new cancer sub-types into expanded therapeutic options for cancer patients.
Ronovo Surgical is an emerging medtech company focused on innovating minimally invasive (MIS) and digital surgery.
Compass Therapeutics is a biopharmaceutical company that focuses on drugging the immune system to treat human diseases.
Trevi Therapeutics is a clinical-stage biopharmaceutical company that develops drugs for treating uremic pruritus.
ORIC Pharmaceuticals is a biopharmaceutical company that develops treatments that target the causes of therapeutic resistance.
Surrozen is a biopharmaceutical that focuses on unlocking the body’s regenerative power to treat injury and disease.
Tarsus Pharmaceuticals is a clinical-stage biopharmaceutical company that develops treatments for diseases with high unmet need.
Aligos Therapeutics is discovering and developing new classes of molecules that interact directly with disease-causing modalities.
ADARx Pharmaceuticals is a genetic medicine company focusing on the base editing of mRNA transcripts.
Neumirna Therapeutics is a pharmaceutical company that develops therapeutics for the treatment of neurological diseases.
Vivo Capital has invested in 105 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Vivo Capital's top investment sectors include Biotechnology, Health Care, Therapeutics, Pharmaceutical, Medical. The firm invests across 14 different industry categories.
Among tracked funding rounds, Celcuity received $500.0M in a Post Ipo Debt round. Vivo Capital's total known invested capital is $5.6B.
Vivo Capital's average investment size is $78.6M across its portfolio of 105 companies.
Recent Vivo Capital portfolio additions include Immunic Therapeutics, Coherus Biosciences, Gyala Therapeutics, Kinaset Therapeutics, Clene Nanomedicine. These companies were founded in 2020 or later.
Discover portfolio companies of other leading venture capital firms and investors.
View All Investors